Gossamer Bio Inc. (GOSS) Reports Q4 Loss of $0.88/sh

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. BROS
3. ARM
4. FIS
5. QCOM
6. EXPE
7. CPAY
8. PAYC
9. SNAP
10. FSLY

Go back to Gossamer Bio Inc. (GOSS) Reports Q4 Loss of $0.88/sh

Gossamer Bio Announces Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Update

February 25, 2021 7:31 AM EST

- Seralutinib (GB002) and GB004 continue to progress through ongoing Phase 2 TORREY and SHIFT-UC clinical trials for Pulmonary Arterial Hypertension (PAH) and Ulcerative Colitis (UC), respectively -

- Topline results for both ongoing Phase 2 trials expected in the first half of 2022, subject to developments in the ongoing COVID-19 pandemic -

- Gossamer to conduct no further clinical development of GB001 or related backup molecule without a partner -

- Cash, cash equivalents and marketable securities totaled $513 million at year-end 2020 -

SAN DIEGO--(BUSINESS... More